Ownership history in Bleichroeder LP Β· 8 quarters on record
This page tracks every 13F SEC filing in which Bleichroeder LP reported a position in IMMIX BIOPHARMA INC (IMMX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Bleichroeder LP outperformed the S&P 500 by +98.8% annually on this IMMX position. Average cost basis: $5.23. Maximum drawdown during holding period: β24.7%.
π₯ Exceptional β beat the S&P 500 by 98.8% per year on this position.
6 quarters analyzed
Best entry: $5.23 (2025 Q4) Β· Worst: $5.23 (2025 Q4)
πͺ Held through 2 major drawdowns (>20%).
2 adds Β· 0 trims. Bought during 0 of 2 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Bleichroeder LP has been actively increasing its IMMX allocation β a bullish signal from insiders.
Currently 0.92% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size